Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide in obesity and prediabetes
NCT05340868Recruiting
- Sponsor
- Medical University of Białystok
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of semaglutide in obesity and prediabetes, sponsored by Medical University of Białystok. Primary endpoints: Change in HbA1c at 3 months and Change in body weight at 3 months. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on NCT05340868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340868.